the Effect of Reiki Application on Depression, Anxiety and Physical Activity in Patient With Multiple Sclerosis

January 6, 2025 updated by: Gülcan Bahçecioğlu Turan, Ataturk University

Investigation of the Effect of Reiki Application on Depression, Anxiety and Physical Activity in Individuals Diagnosed With Relapsing-Remitting Multiple Sclerosis

During Reiki application, individuals may report feeling a slight warm sensation under and near the therapist's hand. The only rule in Reiki practice is that the individual must give permission to the practitioner to facilitate the flow of energy. The person receiving Reiki during the application does not have to believe in Reiki. Because Reiki is universal life energy and is available to everyone. Reiki is generally safe and no serious side effects have been reported. Reiki practice in the last 10 years; It is increasing among physicians, nurses and other healthcare professionals.

This study was planned to investigate the effect of reiki application on depression, anxiety and physical activity in individuals diagnosed with Relapsing-Remitting Multiple Sclerosis.

Geri bildirim gönder Yan paneller

Study Overview

Status

Completed

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Elazıg, Turkey
        • Firat University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Being over 18 years of age
  • Having the ability to use technological devices
  • Not using Reiki and similar integrative treatment methods
  • No verbal communication disability (hearing and speaking)
  • Not having a diagnosed psychiatric disorder
  • Patients who have been receiving Relapsing-Remitting MS treatment for more than three months

Exclusion Criteria:

  • Patients using any complementary alternative treatment methods
  • Patients who cannot communicate by phone to participate in remote reiki application
  • Patients with autoimmune diseases other than multiple sclerosis
  • Patients with communication disabilities
  • Patients with another known neurological system disease (dementia, Alzheimer's, etc.).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Experimental:
Reiki application will be done
Reiki application will be done
No Intervention: Control
Reiki application will not be done

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Beck Depression Scale
Time Frame: 4 week
The scale was administered to investigate each participant's feelings and attitudes regarding the general depressive state. Each patient was asked to read several groups of statements and then mark the one statement in each group that best described how he or she felt "during the past week." BDI, which evaluates four statements describing increasing intensities of depressive symptoms between 0 and 3 points, includes 21 items. Depressive symptoms were classified as follows: minimal-to-moderate depressive symptoms (range 14 to 19), moderate-to-severe depressive symptoms (range 20 to 29), severe depressive symptoms (range 30 to 63).
4 week
Beck Anxiety Scale
Time Frame: 4 week
BAI is a self-rating scale developed by Beck et al. (1988) and used to determine the frequency of anxiety symptoms experienced by individuals. It is a Likert-type scale consisting of 21 items and scored between 0-3. Its validity and reliability in Turkey were determined by Ulusoy et al.
4 week
International Physical Activity Survey
Time Frame: 4 week
There are some scales that can be used in primary care to evaluate physical mobility. One of these is the "International Physical Activity Questionnaire", which was developed by the International Consensus Group consisting of researchers from various countries with the support of the World Health Organization and the Center for Disease Control, to be used to measure physical activity and inactivity in 1997 and 1998; (IPAQ)" is a standard tool. Reliability and/or validity studies were conducted in 14 centers from 12 countries in 2000 for at least two of the four long (IPAQ-long) and four short (IPAQ-SF) forms of the IPAQ. This scale was adapted into Turkish as long form (UF) and short form (SF) under the name "International Physical Activity Questionnaire (UFAA)" and its validity and reliability study was conducted by Sağlam et al. in 2010
4 week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2023

Primary Completion (Actual)

April 1, 2024

Study Completion (Actual)

June 1, 2024

Study Registration Dates

First Submitted

November 8, 2023

First Submitted That Met QC Criteria

November 8, 2023

First Posted (Actual)

November 13, 2023

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

January 6, 2025

Last Verified

January 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Multiple Sclerosis, Relapsing-Remitting

Clinical Trials on Reiki

Subscribe